Literature DB >> 7722840

Transperitoneal closure of the internal ring in incarcerated infantile inguinal hernias.

D Misra1, G Hewitt, S R Potts, S Brown, V E Boston.   

Abstract

Over a 6-year period, 14 infants with a total of 16 inguinal hernias (IH) underwent transperitoneal closure of the internal ring (TPIR). This was performed through a minilaparotomy, using a purse-string suture placed around the internal ring from within. A difficult inguinal dissection of an edematous and friable spermatic cord was avoided. TPIR was performed for incarceration in 13 of the infants and for recurrence of the hernia within 24 hours of herniotomy in one. There were no intraoperative problems, and during follow-up there was no evidence of testicular atrophy or recurrence of the hernia. This suggests that TPIR is a reliable and safe operation in babies for whom the alternative inguinal approach would be difficult. These situations include hernias that are irreducible and early recurrence in which dissection of the cord would risk damage to the vas deferens or testicular vessels.

Entities:  

Mesh:

Year:  1995        PMID: 7722840     DOI: 10.1016/0022-3468(95)90619-3

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  3 in total

1.  Preperitoneal approach for herniotomy in infants: a 9-year review.

Authors:  Vasu Karri; Darren Klass; Sattar Alshryda; Azad Mathur
Journal:  Pediatr Surg Int       Date:  2006-08-30       Impact factor: 1.827

2.  Laparoscopic inguinal hernia repair in children using the percutaneous internal ring suturing technique - own experience.

Authors:  Przemysław K Wolak; Dariusz Patkowski
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2014-01-30       Impact factor: 1.195

3.  Treatment for incarcerated indirect hernia with "Cross-Internal Ring" inguinal oblique incision in children.

Authors:  Xue-Qiang Yan; Jun Yang; Nan-Nan Zheng; Hou-Fang Kuang; Xu-Fei Duan; Hong-Qiang Bian
Journal:  J Res Med Sci       Date:  2017-09-26       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.